Biotech · Private company
Kangpu Biopharmaceuticals, Ltd.
Track this companyFree. Adds Kangpu Biopharmaceuticals, Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- KPG-818 high dose in phase 1bPhase 2 · SLE; DrugClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818 low dose in phase 1bPhase 2 · SLE; DrugClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818 low dose in phase 2aPhase 2 · SLE; DrugClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818 mid dose in phase 1bPhase 2 · SLE; DrugClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818 mid dose in phase 2aPhase 2 · SLE; DrugClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818 ultra-high dose in phase 1bPhase 2 · SLE; DrugClinicalTrials.gov · fetched Nov 12, 2026
- Enzalutamide or Abiraterone or ApalutamidPhase 1 · Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818Phase 1 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- KPG-818Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies SubjectsPHASE1 · COMPLETED · started Sep 13, 2021ClinicalTrials.gov NCT04283097 · fetched Nov 12, 2026
- Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLEPHASE1_PHASE2 · COMPLETED · started Jun 3, 2021ClinicalTrials.gov NCT04643067 · fetched Nov 12, 2026
- Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC PatientsPHASE1 · COMPLETED · started Nov 26, 2019ClinicalTrials.gov NCT03569280 · fetched Nov 12, 2026
- Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy SubjectsPHASE1 · COMPLETED · started May 1, 2019ClinicalTrials.gov NCT03949426 · fetched Nov 12, 2026